File Download
Supplementary

Conference Paper: Thymomatous myasthenia gravis among Hong Kong Chinese

TitleThymomatous myasthenia gravis among Hong Kong Chinese
Authors
Issue Date2010
PublisherEuropean Neurological Society (ENS).
Citation
The 20th Annual Meeting of the European Neurological Society (ENS 2010), Berlin, Germany, 19-23 June 2010. How to Cite?
AbstractBACKGROUND: Myasthenia gravis (MG) is an autoimmune disorder targeting skeletal muscle acetylcholine receptor. Thymoma is associated in some patients with myasthenia gravis, the majority of whom present with symptoms of MG before detection of underlying thymoma. AIM: to study clinical and serological characteristics of Chinese thymomatous MG patients. METHODS: Autoimmune MG patients with thymomectomy and histologically confirmed thymoma followed up in our hospital for at least 12 months were studied. RESULTS: Total 37 Chinese MG patients with histology-proven thymoma were retrospectively studied. The mean MG symptom onset age was 48.5 years (range 25-81), 25 (68%) were female. The mean follow-up duration was 4.9 years (range1-15). MG symptoms preceded detection of thymoma in the majority (31 patients, 84%), in 6 patients thymoma detection preceded MG symptoms onset by 1-8 years. 19 patients (51%) had early onset MG (before 50 years of age). All patients were seropositive for acetylcholine receptor antibodies and 30 patients (81%) seropositive for striated muscle antibodies. Eleven patients (30%) had experienced myasthenic crisis and the worst MGFA clinical severity grade were class I (6 patients), class II (3), class III (8), class IV (9) and class V (11); hence 31 (84%) had generalized MG and 6 (16%) had ocular MG. 27 patients (73%) had history of corticosteroid therapy, 22 (60%) require azathioprine, 2 require other immunosuppressant (1 mycophenolate mofetil, 1 cyclosporin A). All 37 patients had good or satisfactory MG clinical outcome measured by MGFA post-intervention status (2 pharmacological remission, 23 minimal manifestation, 12 improved) though one patient died from metastatic thymoma. CONCLUSION: Thymoma MG was clinically severe with frequent myasthenic crises, but response to conventional immunosuppressive therapies are satisfactory.
DescriptionSession - Muscle disorders
Persistent Identifierhttp://hdl.handle.net/10722/105549

 

DC FieldValueLanguage
dc.contributor.authorChan, KHen_HK
dc.contributor.authorTsang, JWHen_HK
dc.contributor.authorMak, WWen_HK
dc.contributor.authorLiu, HHWen_HK
dc.contributor.authorHo, SLen_HK
dc.contributor.authorCheung, RTFen_HK
dc.date.accessioned2010-09-25T22:38:48Z-
dc.date.available2010-09-25T22:38:48Z-
dc.date.issued2010en_HK
dc.identifier.citationThe 20th Annual Meeting of the European Neurological Society (ENS 2010), Berlin, Germany, 19-23 June 2010.-
dc.identifier.urihttp://hdl.handle.net/10722/105549-
dc.descriptionSession - Muscle disorders-
dc.description.abstractBACKGROUND: Myasthenia gravis (MG) is an autoimmune disorder targeting skeletal muscle acetylcholine receptor. Thymoma is associated in some patients with myasthenia gravis, the majority of whom present with symptoms of MG before detection of underlying thymoma. AIM: to study clinical and serological characteristics of Chinese thymomatous MG patients. METHODS: Autoimmune MG patients with thymomectomy and histologically confirmed thymoma followed up in our hospital for at least 12 months were studied. RESULTS: Total 37 Chinese MG patients with histology-proven thymoma were retrospectively studied. The mean MG symptom onset age was 48.5 years (range 25-81), 25 (68%) were female. The mean follow-up duration was 4.9 years (range1-15). MG symptoms preceded detection of thymoma in the majority (31 patients, 84%), in 6 patients thymoma detection preceded MG symptoms onset by 1-8 years. 19 patients (51%) had early onset MG (before 50 years of age). All patients were seropositive for acetylcholine receptor antibodies and 30 patients (81%) seropositive for striated muscle antibodies. Eleven patients (30%) had experienced myasthenic crisis and the worst MGFA clinical severity grade were class I (6 patients), class II (3), class III (8), class IV (9) and class V (11); hence 31 (84%) had generalized MG and 6 (16%) had ocular MG. 27 patients (73%) had history of corticosteroid therapy, 22 (60%) require azathioprine, 2 require other immunosuppressant (1 mycophenolate mofetil, 1 cyclosporin A). All 37 patients had good or satisfactory MG clinical outcome measured by MGFA post-intervention status (2 pharmacological remission, 23 minimal manifestation, 12 improved) though one patient died from metastatic thymoma. CONCLUSION: Thymoma MG was clinically severe with frequent myasthenic crises, but response to conventional immunosuppressive therapies are satisfactory.-
dc.languageengen_HK
dc.publisherEuropean Neurological Society (ENS).-
dc.relation.ispartofAnnual Meeting of the European Neurological Society, ENS 2010en_HK
dc.titleThymomatous myasthenia gravis among Hong Kong Chineseen_HK
dc.typeConference_Paperen_HK
dc.identifier.emailChan, KH: koonho@hku.hken_HK
dc.identifier.emailTsang, JWH: jwhtsang@hku.hken_HK
dc.identifier.emailMak, WW: wwwmak@hku.hken_HK
dc.identifier.emailHo, SL: slho@hku.hken_HK
dc.identifier.emailCheung, RTF: rtcheung@hku.hk-
dc.identifier.authorityChan, KH=rp00537en_HK
dc.identifier.authorityTsang, JWH=rp00278en_HK
dc.identifier.authorityHo, SL=rp00240en_HK
dc.description.naturelink_to_OA_fulltext-
dc.identifier.hkuros169944en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats